OncorusÂ Inc (ONCR)

Stock Card

$0.13

$0.00 (-3.08%)

As on 29-Dec-2023 14:55EDT

Market cap

$3 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.1

Div. Yield

0 %

OncorusÂ Inc (ONCR) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-60 Mln
ROE

-1.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.4
Debt to Equity

0
Book Value

$--
EPS

$-3.6
Face value

--
Shares outstanding

26,094,800

6 Years Aggregate

CFO

$-206.04 Mln

EBITDA

$-221.78 Mln

Net Profit

$-238.03 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
OncorusÂ Inc (ONCR)	-50.2	500.0	375.5	-48.1	-84.6	--	--
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5

As on 29-Dec-2023 | *As on 31-Aug-2026

Company	2023	2022	2021
OncorusÂ Inc (ONCR)	-50.2	-95.2	-83.7
BSE Sensex	18.7	4.4	22.0
BSE Sensex	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
OncorusÂ Inc (ONCR)	0.1	3.3	0.0	-94.3	--	-169.7	--	0.1
Arrowhead Pharmaceuticals (ARWR)	82.4	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	70.9	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.6	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	106.5	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	359.4	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	540.0	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	594.0	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	350.3	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	147.8	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About OncorusÂ Inc (ONCR)

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic... thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts. Read more

Non-Exec. Chairman

Dr. Mitchell H. Finer Ph.D.
Non-Exec. Chairman

Dr. Mitchell H. Finer Ph.D.
Headquarters

Cambridge, MA
Website

https://www.oncorus.com

FAQs for OncorusÂ Inc (ONCR)

What is the current share price of OncorusÂ Inc (ONCR) Today?

The share price of OncorusÂ Inc (ONCR) is $0.13 (NASDAQ) as of 29-Dec-2023 14:55 EDT. OncorusÂ Inc (ONCR) has given a return of -84.59% in the last 3 years.

What is the current PB & PE ratio of OncorusÂ Inc (ONCR)?

Since, TTM earnings of OncorusÂ Inc (ONCR) is negative, P/E ratio is not available.
The P/B ratio of OncorusÂ Inc (ONCR) is 0.11 times as on 29-Dec-2023, a 98 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.